aTyr Pharma Inc

aTyr Pharma maintains a strong liquidity position with a current ratio of 5.3, supported by $10.74 million in cash and equivalents and total assets of $93.00 million. The company's debt-to-equity ratio is 0.01, indicating minimal leverage, and its market cap of $90.38 million is modest relative to its book value of $67.48 million, as reflected in a price-to-book ratio of 1.34.

The company is currently unprofitable, with a net loss of $74.12 million and an operating loss of $77.63 million. Return on equity is -109.84%, and return on assets is -7.97%, both significantly below industry norms for biotechnology firms. The enterprise value to revenue ratio of 423.84 suggests a high valuation relative to its current revenue of $190.00 million, which is driven by a small market cap and no debt.

aTyr Pharma's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's operations are entirely focused on the development of therapeutic candidates, with no revenue from commercialized products. This concentration increases exposure to clinical trial outcomes and regulatory delays.

The company's growth trajectory is uncertain, with no revenue growth reported in the latest period. Analysts have issued a wide range of price targets, from $1.00 to $20.00, with a mean of $6.36 and a median of $1.00. The mean recommendation score of 2.60 suggests a mixed outlook, with seven "hold" ratings and only three "buy" or "strong buy" ratings.

aTyr Pharma faces significant financial risk due to its negative operating and free cash flows, which are -$61.99 million and -$73.50 million, respectively. The company has no immediate liquidity or dilution flags, but its capital expenditures of -$77,000 suggest minimal investment in infrastructure. The risk assessment indicates low dilution potential, but the absence of positive cash flows raises concerns about long-term sustainability.

Recent filings and transcripts have not revealed any major events or strategic shifts. The company continues to focus on its clinical pipeline, with no new product launches or partnerships disclosed in the latest period. The lack of recent developments may contribute to the wide dispersion in analyst price targets.